MapLight Therapeutics, Inc. (MPLT) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $830.62M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-944.00K; Retained Earnings (Accumulated Deficit)USD $-481.38M.
- 2026-03-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $821.90M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-883.00K; Retained Earnings (Accumulated Deficit)USD $-421.19M.
- 2025-12-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $819.12M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-228.00K; Retained Earnings (Accumulated Deficit)USD $-360.52M.
- 2025-09-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $6.75M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $46.00K; Retained Earnings (Accumulated Deficit)USD $-280.97M.
MapLight Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.00K | $830.62M | $-944.00K | $-481.38M | $348.30M | 3 month · $8.63M | (m) |
| 2026-03-31 | $5.00K | $821.90M | $-883.00K | $-421.19M | $399.83M | 3 month · $9.64M | 3 month · $7.50M |
| 2025-12-31 | $5.00K | $819.12M | $-228.00K | $-360.52M | $458.37M | 12 month · $36.01M | (m) |
| 2025-09-30 | $0.00 | $6.75M | $46.00K | $-280.97M | $-274.18M | 3 month · $125.00K | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | $-245.06M | 3 month · $148.00K | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | $-215.83M | 3 month · $212.00K | (m) |
| 2024-12-31 | $0.00 | $5.58M | $163.00K | $-199.37M | $-193.63M | 12 month · $1.08M | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | $-172.37M | 3 month · $354.00K | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | $-154.33M | 3 month · $245.00K | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | $-136.00M | 3 month · $267.00K | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | $-117.58M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |